Following the NMPA's approval for the marketing application of infliximab biosimilar (CMAB008) on July 14, Kexing Biopharm quickly started working on an overseas sales plan for the drug.

On July 23, a ceremony was held in Taizhou to confirm the first drug registration countries and hand over technical files for commercial cooperation of CMAB008 (infliximab) in the overseas market. The ceremony was held by Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", stock code: 688136.SH) and Taizhou Mabtech Pharmaceutical Co., Ltd. (hereinafter referred to as "Taizhou Mabtech"), a wholly-owned subsidiary of Mabpharm Limited (hereinafter referred to as "Mabpharm", stock code: 2181.HK). Kexing Biopharm plans to initiate drug registration in 17 countries, including Brazil, India, Egypt and Indonesia, with some countries expected to start sales in the near future.

The signing ceremony was presided over by Li Yunfeng, ED & CFO of Mabpharm. Other attendees included the following: Wu Xiang, Secretary of Party Working Committee & Director of Management Committee, Jiang Peng, member of Party Working Committee & Deputy Director of Management Committee, Ju Bin, Director of Party and Government Office, Taizhou Medical New & Hi-tech Industrial Development Zone; General Manager Zhao Yanqing and Deputy General Manager Shao Ke of Kexing Biopharm; Wang Hao, Executive Director of Mabpharm; Tao Jing, Executive Director of Mabpharm & General Manager of Taizhou Mabtech.

CMAB008 (infliximab) is mainly used to treat ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis in adults, Crohn's disease, fistulizing Crohn's disease and psoriasis in adults and children over 6 years of age. According to data from Fierce Pharma's website, infliximab saw global sales worth $4,195 million in 2020, ranking top 20 in global drug sales.

CMAB008 (infliximab) was the first infliximab biosimilar drug approved for marketing in China, while also being Taizhou Mabtech's first marketed product. In Taizhou Mabtech search for partners to realize fast drug marketing in the global market, Kexing Biopharm is a perfect fit. Kexing Biopharm has been recognized in the industry in recent years for its business strength and results overseas, as its overseas sales network keeps expanding over the years, thanks to its active involvement in overseas market layout. CMAB008 is another antibody drug in the commercial stage introduced by Kexing Biopharm. With this strong cooperation, Kexing Biopharm can enrich its product pipeline and improve its market layout. Furthermore, thanks to years of international operation experience, Kexing Biopharm has matured and optimized its overseas commercialization, providing strong support to China-made, high-quality biologics for marketing and promotion in foreign countries, helping to serve patients worldwide.